ArticleFrontiers in pharmacology2022

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure.

Jin Lei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.